BioGaia axes Nestlé tie-up
This article was originally published in OTC Bulletin & The Rose Sheet
BioGaia’s royalty agreement with Nestlé – for sales of growing up milk with its probiotic strain Lactobacillus reuteri – is to be terminated at the end of the year.
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.